The six ethical issues most commonly identified in research are informed consent, privacy and confidentiality, beneficence (minimizing harm), justice in participant selection, voluntary participation, and scientific integrity. These principles apply across disciplines, from clinical trials to social science surveys, and they form the foundation of how ethical review boards evaluate every study involving human subjects.
1. Informed Consent
Informed consent is the requirement that every research participant fully understands what they’re agreeing to before a study begins. This isn’t just signing a form. Federal guidelines from the Office for Human Research Protections specify that participants must be told the study involves research, how long it will last, what procedures are involved, and which of those procedures are experimental. They must also learn about any foreseeable risks or discomforts, any potential benefits to themselves or others, and whether alternative treatments or procedures exist.
Beyond the basics, the consent process must explain how the researchers will protect the participant’s identity, who to contact with questions or if something goes wrong, and whether compensation or medical treatment is available if the study causes injury. Critically, participants must be told that their involvement is entirely voluntary and that they can quit at any time without losing any benefits they’re otherwise entitled to. For consent to be valid, the person giving it needs to genuinely understand all of this, not just receive it on paper.
2. Privacy and Confidentiality
Researchers collect deeply personal information, from medical histories to genetic data, and protecting that information is a core ethical obligation. The National Institutes of Health requires that participant data be de-identified to the greatest extent possible while still maintaining scientific usefulness. Unless someone explicitly consents to having their identifiable information shared, data should only leave the research team in a de-identified format.
Even when data is technically de-identified, NIH recommends controlled-access sharing through formal data use agreements that spell out who can access the information, what restrictions apply, and what oversight is in place. For particularly sensitive research, Certificates of Confidentiality provide legal protection by prohibiting disclosure of identifying information for non-research purposes. These certificates cover the data and all copies of it permanently, shielding participants even after a study ends. The practical takeaway: privacy protections are layered, combining technical steps like removing names and identifiers with legal safeguards and institutional agreements.
3. Beneficence and Minimizing Harm
Beneficence is the principle that research should maximize potential benefits while minimizing risks to participants. Every study involving human subjects must undergo a risk-benefit assessment before it can proceed. Review boards evaluate whether the favorable effects of the research outweigh the unfavorable ones, looking at the likelihood and severity of potential harms alongside the value of the knowledge that might be gained.
This assessment isn’t purely mathematical. It involves both evidence and judgment. Researchers present data on expected outcomes and their variability, but the final determination of whether the balance tips toward benefit requires weighing factors that can’t always be quantified, like the burden a procedure places on a participant’s daily life or the importance of the research question to a broader population. The FDA requires institutional review boards to confirm that risks are minimized through sound study design and that any remaining risks are reasonable relative to the anticipated benefits. A study that exposes participants to significant discomfort for trivial scientific gain won’t pass review, no matter how well designed the protocol is.
4. Justice in Participant Selection
The principle of justice asks who bears the burdens of research and who reaps the benefits. Historically, marginalized groups (prisoners, economically disadvantaged communities, racial minorities) were disproportionately recruited for risky studies while the resulting treatments primarily benefited wealthier populations. The ethical standard now requires equitable selection of participants, meaning the people who take on the risks of a study should have a fair chance of benefiting from its results.
NIH guidelines mandate the inclusion of adequate numbers of women in clinical trials, a policy that emerged after decades of research conducted almost exclusively on men. The same logic extends to elderly participants, people with HIV, individuals with mental illness, and other groups historically excluded from studies whose findings were then applied to them anyway. Eligibility criteria must be justified by the researchers, and ethics committees are expected to push back on exclusions that seem unnecessary. The goal is broad representation so that research findings are actually valid for the diverse populations who will use the treatments or interventions being studied.
5. Voluntary Participation
Participation in research must be freely chosen, without coercion or undue influence. This sounds straightforward, but it becomes complicated in practice. A prisoner offered early release for joining a study, a student whose professor is recruiting participants, or a patient whose doctor is also the lead researcher all face subtle pressures that can undermine genuine voluntariness. Federal regulations specifically flag children, prisoners, pregnant women, people with mental disabilities, and economically or educationally disadvantaged individuals as populations vulnerable to these pressures.
Protecting voluntariness goes beyond the initial consent. Participants must be able to withdraw at any point without penalty. Researchers and review boards are expected to build in additional safeguards for vulnerable populations, which might include having an independent advocate present during the consent process or verifying that the participant understands they have alternatives to joining the study. For individuals with questionable capacity to consent, such as people with cognitive impairments, investigators may need to assess whether the person truly grasps the voluntary nature of participation before enrollment.
6. Scientific Integrity
Research that produces unreliable results wastes resources, misleads other scientists, and can directly harm the public when flawed findings influence medical decisions or policy. The Office of Research Integrity defines research misconduct as fabrication, falsification, or plagiarism. Fabrication means making up data or results entirely. Falsification means manipulating materials, equipment, or processes, or changing or omitting data so that the research record doesn’t accurately reflect what happened. Plagiarism is presenting someone else’s work or ideas as your own. Honest errors and legitimate differences in interpretation do not count as misconduct.
Beyond outright fraud, scientific integrity also encompasses subtler issues. Conflicts of interest, such as financial ties to a company whose product is being tested, can bias study design or interpretation even without conscious dishonesty. Redundant publication, where researchers publish the same data in multiple journals to inflate their publication record, distorts the scientific literature by making a single finding look like it has been replicated when it hasn’t. Authorship disputes arise when people who contributed meaningfully to a study are left off the author list, or when people who didn’t contribute are added for political reasons. All of these undermine the trustworthiness of the research enterprise.
How These Principles Are Enforced
In the United States, the primary regulatory framework is the Common Rule, formally known as 45 CFR 46, which was most recently revised in 2018. It provides baseline protections for all human research subjects and adds extra safeguards for specific vulnerable populations: pregnant women and fetuses, prisoners, and children each have their own subpart with additional requirements.
Before any federally funded study involving human participants can begin, it must be reviewed and approved by an Institutional Review Board. The IRB’s job is to verify that risks are minimized, that the risk-benefit balance is acceptable, that consent procedures are adequate, and that participant selection is equitable. For research involving animals, a parallel framework called the 3Rs guides ethical practice: replacement (using non-animal alternatives when possible), reduction (using the fewest animals necessary to achieve valid results), and refinement (minimizing pain and distress for the animals that are used). Originally proposed by scholars Russell and Burch, this framework is now embedded in animal research regulations worldwide.
As research increasingly involves large-scale data collection and artificial intelligence, new ethical dimensions are emerging. AI-driven studies raise concerns about algorithmic bias in participant enrollment, privacy risks from combining massive genetic datasets, and a lack of transparency in how algorithms reach their conclusions. These challenges don’t replace the six core issues. They extend them into territory where traditional consent forms and review processes may need to evolve.